Corcept Therapeutics

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Joshua M. Murray has joined the company's Board of Directors.

Corcept Therapeutics Appoints Joshua M. Murray to Board of Directors

Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well.

Corcept's (CORT) Lead Drug Korlym Aids Growth Amid Competition

Corcept (CORT) reports wider-than-expected loss in the first quarter of 2021, with its revenues also missing estimates.

Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2021 Results - Earnings Call Transcript

MENLO PARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its results for the quarter ended March 31, 2021.

Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results

MENLO PARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced positive results from its 178-patient, controlled, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.

Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer

Corcept Therapeutics (CORT) has been struggling lately, but the selling pressure may be coming to an end soon

Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy?

Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Corcept Therapeutics (CORT) Q1 Earnings Expected to Decline

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Why Is Corcept (CORT) Down 11.1% Since Last Earnings Report?

Corcept (CORT) commences phase Ib study on relacorilant in combination with Keytruda for treating patients with adrenal cancer with cortisol excess.

Corcept (CORT) Begins Adrenal Cancer Study on Relacorilant

MENLO PARK, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of the first patient in the Phase 1b trial of relacorilant in combination with the PD-1 checkpoint inhibitor pembrolizumab (Merck's medication, Keytruda®) in patients with adrenal cancer with cortisol excess.

Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess

Corcept's (CORT) earnings meet estimates in the fourth quarter of 2020 while revenues miss the same.

Corcept (CORT) Q4 Earnings In Line, Revenues Miss Estimates

MENLO PARK, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter- and year-ended December 31, 2020.

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results

Amneal Pharmaceuticals

AMRX vs. CORT: Which Stock Is the Better Value Option?

AMRX or CORT: Which Is the Better Value Stock Right Now?

Acasti Pharma

Kaleido Biosciences Inc

Transmedics Group Inc

Corcept Therapeutics (NASDAQ: CORT) shares were trading lower Tuesday after the company reported preliminary fourth-quarter sales results and issued fiscal year 2021 sales guidance. Corcept Therapeutics Inc is engaged in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

Why Corcept Therapeutics, Acasti Pharma And More Are Moving Today

Corcept (CORT) provides preliminary revenue figures for fourth-quarter and full-year 2020. The company also issues revenue guidance for 2021.

Corcept (CORT) Posts Preliminary '20 Results, Gives 2021 View

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q4 2020 Results - Earnings Call Transcript

Financial Highlights, 2021 Revenue Guidance and Legal Update

Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update

Corcept Therapeutics (CORT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Corcept Therapeutics (CORT) Might Surprise This Earnings Season

MENLO PARK, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its preliminary 2020 fourth quarter and full-year financial results and provide a corporate update on February 8, 2021. The company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Corcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference Call

CRISPR Therapeutics

Fate Therapeutics

Jounce Therapeutics

Lexicon Pharmaceuticals

Time will always be on the investor's side.

Got $5,000 and 5 Years to Wait? Buy These 5 Hot Biotech Stocks Now

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

Corcept (CORT) Up More Than 50% in Past 3 Months: Here's Why

On Friday, Corcept Therapeutics got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Corcept Therapeutics Sees Its Composite Rating Rise To 96 appeared first on Investor's Business Daily.

Corcept Therapeutics Sees Its Composite Rating Rise To 96

Why Is Corcept (CORT) Up 25.8% Since Last Earnings Report?

MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Gillian M. Cannon, PhD, has joined the company's Board of Directors.

News for Corcept Therapeutics Stock (CORT)